12 Posts Not To Miss From Day 2 of ASCOBT24!
This Year the ASCO Breakthrough (ASCOBT24) is being held in Yokohama, Japan from 8th to 10th of August, jointly organized by the Japan Society of Clinical Oncology (JSCO) and Japanese Society of Medical Oncology (JSMO). It focuses on showcasing significant advancements and innovations in oncology.
Here are some highlights from Day 2 of ASCOBT24 that you should not miss!
“Day 2 ASCOBT24 began with terrific and important keynote by Dr. Raffaella Casolino of WHO on a topic I’m so passionate about, Building Equity in Cancer Care: From Policy to Action. Also an honor to see JSCO Chairman Dr. Takayuki Yoshino. I love all the global connections taking place!”
“Important conversation about global disparities in cancer care accessibility.
- 62% with accesss to HER2 testing and trastuzumab
- 51% with access to EGFR testing and EGFR TKI
Despite life-saving and availability of biosimilars and generics.”
“This year’s program tries to be as inclusive as possible. Last but not least – a thorough discussion on Health Economics in Cancer Care across health systems and between payers and practitioners.”
“Happening now ASCOBT24 Day 2
- Balancing Health Economics with New Cancer Treatments
- Access to Value-Based and Sustainable Care in High-Income Countries
- Speaker: Lydia Loke“
“Thomas Blank kicks off expert panel on neoadjuvant immunotherapy across tumour types.
Lessons from melanoma:
- Surgical de-escalation after good response to neo-adjuvant IO
- Rational adjuvant treatments for non-PCR
- Phase 3 NADINA ASCO plenary”
“What a wonderful keynote at #ASCOBT24 by Raffaella Casolino/WHO highlighting the importance of addressing (among other points) the inequities in the global clinical trials landscape. War, government policy, ‘brain-drain’ lead to uneven distribution of resources.”
“Very thankful for the support by ASCO for young investigators to present and participate in this international meeting in Asia.
Proud of the strong showing by Chua Lab.”
“Health quality assessment in EV302 trial is now presented at ASCOBT24. Clinically meaningful improvement was seen from EV pembro. A transient decline was seen at week 3 but recovered to baseline.”
“Love the session title.
‘Fighting Cancer with Robots and Lasers’
Emerging techniques in surgery and RT to improve outcomes and reduce morbidity/mortality.”
“Dr Jinsil Seong
Neoadjuvant radiotherapy downstages HCC to allow resection and lower recurrence rates.
Liver RT allows for debulking, and immune-microenvironment remodelling to increase response to systemic immunotherapy.
Combination strategy trials coming.”
“ASCOBT24 It is exceptionally that this oncology meeting invites a health economics expert to discuss how public funds are dispersed. Lydia Loke from Singapore convinced a room of cancer specialists to vote for Diabetes 100%.”
“Excited to catch Day 2 Opening Remarks and Keynote from ASCOBT24 in Yokohama LIVE thanks to the American Society of Clinical Oncology (ASCO) meetings mobile app.”
See 15 Posts Not To Miss From Day 1 of ASCOBT24.
For the latest updates on ASCOBT24, visit oncodaily.com